Advertisement

Drug Delivery and Translational Research

, Volume 4, Issue 5–6, pp 389–394 | Cite as

Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells

  • Te-Wei Chu
  • Ken M. Kosak
  • Paul J. Shami
  • Jindřich KopečekEmail author
Clinical Research

Abstract

A new drug-free nanotherapeutic approach for B-cell malignancies was developed. Exposure of B-cells to an anti-CD20 Fab’-morpholino oligonucleotide1 (MORF1) conjugate decorated the cell surface with MORF1; further exposure of the decorated cells to multivalent polymer-oligonucleotide2 conjugates (P-MORF2) resulted in CD20 clustering at the cell surface with induction of apoptosis. We evaluated this concept in chronic lymphocytic leukemia (CLL) cells isolated from ten patients. Apoptosis and cytotoxicity were observed in eight samples, including two samples with the 17p13 deletion, which suggested a p53-independent mechanism of apoptosis induction. When compared to an anti-CD20 monoclonal antibody (mAb), the nanotherapeutic showed significantly more potent apoptosis-inducing activity and cytotoxicity. This was due to the multivalency effect (eight binding sites per polymer chain) of our design in comparison to the divalent mAb. In conclusion, we have developed a novel and potent therapeutic system against CLL and other B-cell malignancies with significant advantages over conventional chemoimmunotherapy.

Keywords

CLL B-cell CD20 Apoptosis HPMA copolymer Nanomedicine 

Notes

Acknowledgments

This work was supported in part by NIH grant GM95606 (to J.K.) from the National Institute of General Medical Sciences and the University of Utah Research Foundation. The authors thank Dr. Ruozhen Hu for assisting with cell cycle analysis and Dr. Jiyuan Yang and Dr. Rui Zhang for helpful discussions.

Conflict of interest

J.K. and T.-W.C. are inventors on a pending US patent application (PCT/US2014/023784; assigned to the University of Utah) related to this work. J.K. is Chief Scientific Advisor and P.J.S. Chief Medical Advisor for Bastion Biologics. Otherwise, the authors declare no relevant financial interests.

Informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014;64:9–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis. 2000;26:133–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Zhang N, Khawli LA, Hu P, Epstein AL. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin’s lymphomas. Clin Cancer Res. 2005;11:5971–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Chu T-W, Yang J, Kopeček J. Anti-CD20 multivalent HPMA copolymer-Fab’ conjugates for the direct induction of apoptosis. Biomaterials. 2012;33:7174–81.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Chu T-W, Yang J, Zhang R, Sima M, Kopeček J. Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis. ACS Nano. 2014;8:719–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584–91.Google Scholar
  7. 7.
    Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the era of targeted therapy for chronic lymphocytic leukemia: Impact on the practicing clinician. J Clin Oncol. 2014;32:3039–47.CrossRefGoogle Scholar
  8. 8.
    van der Kolk LE, Evers LM, Omene C, et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia. 2002;16:1735–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644–52.PubMedGoogle Scholar
  10. 10.
    Johnson RN, Kopečková P, Kopeček J. Synthesis and evaluation of multivalent branched HPMA copolymer − Fab′ conjugates targeted to the B-cell antigen CD20. Bioconjug Chem. 2009;20:129–37.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Johnson RN, Kopečková P, Kopeček J. Biological activity of anti-CD20 multivalent HPMA copolymer − Fab’ conjugates. Biomacromolecules. 2012;13:727–35.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Aluri SR, Shi P, Gustafson JA, et al. A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody. ACS Nano. 2014;8:2064–76.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhang Z, Eckert MA, Ali MM, et al. DNA-scaffolded multivalent ligands to modulate cell function. ChemBioChem. 2014;15:1268–73.PubMedCrossRefGoogle Scholar
  14. 14.
    Pan H, Yang J, Kopečková P, Kopeček J. Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction. Biomacromolecules. 2011;12:247–52.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Yang J, Luo K, Pan H, Kopečková P, Kopeček J. Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelic polyHPMA conjugates. React Funct Polym. 2011;71:294–302.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Zhang R, Yang J, Sima M, Zhou Y, Kopeček J. Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc Natl Acad Sci U S A. 2014;111:12181–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Danilov AV. Targeted therapy in chronic lymphocytic leukemia: Past, present, and future. Clin Ther. 2013;35:1258–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv. 2001;19:435–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Gunn J, Park SI, Veiseh O, Press OW, Zhang M. A pretargeted nanoparticle system for tumor cell labeling. Mol Biosyst. 2011;7:742–8.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Controlled Release Society 2014

Authors and Affiliations

  • Te-Wei Chu
    • 1
  • Ken M. Kosak
    • 2
  • Paul J. Shami
    • 1
    • 2
  • Jindřich Kopeček
    • 1
    • 3
    • 4
    Email author
  1. 1.Department of Pharmaceutics and Pharmaceutical ChemistryUniversity of UtahSalt Lake CityUSA
  2. 2.Division of Hematology and Hematologic Malignancies and Huntsman Cancer InstituteUniversity of UtahSalt Lake CityUSA
  3. 3.Department of BioengineeringUniversity of UtahSalt Lake CityUSA
  4. 4.University of UtahSalt Lake CityUSA

Personalised recommendations